WO2010118200A3 - Liposomal formulations of tocopheryl amides - Google Patents

Liposomal formulations of tocopheryl amides Download PDF

Info

Publication number
WO2010118200A3
WO2010118200A3 PCT/US2010/030342 US2010030342W WO2010118200A3 WO 2010118200 A3 WO2010118200 A3 WO 2010118200A3 US 2010030342 W US2010030342 W US 2010030342W WO 2010118200 A3 WO2010118200 A3 WO 2010118200A3
Authority
WO
WIPO (PCT)
Prior art keywords
tocopheryl
amides
formulations
administration
dosage forms
Prior art date
Application number
PCT/US2010/030342
Other languages
French (fr)
Other versions
WO2010118200A2 (en
Inventor
Brian Salvatore
Jaroslav Turanek
Jiri Neuzil
Original Assignee
Brian Salvatore
Jaroslav Turanek
Jiri Neuzil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901523A external-priority patent/AU2009901523A0/en
Priority claimed from US12/755,649 external-priority patent/US20100260830A1/en
Application filed by Brian Salvatore, Jaroslav Turanek, Jiri Neuzil filed Critical Brian Salvatore
Publication of WO2010118200A2 publication Critical patent/WO2010118200A2/en
Publication of WO2010118200A3 publication Critical patent/WO2010118200A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulations of N-chroman dicarboxylic acid derivatives and their bioisosteres in liposomal systems. Lyophilized liposomal dosage forms of N-chromans, are found to be stable, to achieve therapeutically meaningful plasma levels on administration to a mammalian host, and to demonstrate selective pro-apoptotic oncolytic properties in vivo. Advantageously, these formulations overcome the systemic toxicity that characterized their administration by other dosage forms.
PCT/US2010/030342 2009-04-08 2010-04-08 Liposomal formulations of tocopheryl amides WO2010118200A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2009/901523 2009-04-08
AU2009901523A AU2009901523A0 (en) 2009-04-08 Liposomal Formulations of Tocopheryl Amides
US12/755,649 US20100260830A1 (en) 2009-04-08 2010-04-07 Liposomal Formulations of Tocopheryl Amides
US12/755,649 2010-04-07

Publications (2)

Publication Number Publication Date
WO2010118200A2 WO2010118200A2 (en) 2010-10-14
WO2010118200A3 true WO2010118200A3 (en) 2011-03-24

Family

ID=42936870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030342 WO2010118200A2 (en) 2009-04-08 2010-04-08 Liposomal formulations of tocopheryl amides

Country Status (1)

Country Link
WO (1) WO2010118200A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006560B (en) * 2012-12-12 2014-10-15 上海市第六人民医院 Hyaluronic acid oligosaccharide encased paclitaxel liposome and preparation method thereof
CN114209848B (en) * 2021-12-27 2024-02-23 中国科学技术大学 Preparation method and application of platinum peptide copolymer with siRNA transport function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142182A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Long circulating liposome
US20060034908A1 (en) * 2003-02-11 2006-02-16 Neopharm, Inc. Manufacturing process for liposomal preparations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034908A1 (en) * 2003-02-11 2006-02-16 Neopharm, Inc. Manufacturing process for liposomal preparations
US20050142182A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Long circulating liposome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIROAKI JIZOMOTO ET AL.: "pH-Sensitive liposomes composed of tocopherol hemis uccinate and of phosphatidylethanolamine including tocopherol hemisuccinate", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1213, 1994, pages 343 - 348 *
JAROSLAV TURANEK ET AL: "Liposomal formulation of alpha-tocopheryl maleamide: In vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 237, 2009, pages 249 - 257 *
KARLA A. LAWSON ET AL: "Novel Vitamin E Analogue Decreases Syngeneic Mouse Mammary Tumor Burden and Reduces Lung Metastasis", MOLECULAR CANCER THERAPEUTICS, vol. 2, 2003, pages 437 - 444 *
YOUNG-HWA KANG ET AL.: "Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells", CANCER LETTERS, vol. 217, 2005, pages 181 - 190 *

Also Published As

Publication number Publication date
WO2010118200A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
CA2873274C (en) Pulmonary delivery of messenger rna
PH12015501421A1 (en) Long-acting formulations of insulin
IL199945A (en) Cholic acid derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2011009539A8 (en) ε-POLYLYSINE CONJUGATES AND USE THEREOF
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
BR112014009305A2 (en) freeze-dried liposomes
MX2011002783A (en) Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof.
MX2012000414A (en) Pyridin-4-yl derivatives.
EP3626253A3 (en) Stable formulations of linaclotide
WO2011119995A3 (en) Formulations and methods of use
IL211946A (en) Derivatives of (2-hydroxy-2-phenyl-1-pyrrolidin-1-ylmethyl-ethyl)carbamic acid phenyl ester, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
WO2010088565A8 (en) Nucleic acid delivery using modified chitosans
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL202248A (en) 3-(imidazol-2-yl)-pyrazolo[3,4-b]pyridine-1-acetic acid 4-(3-methoxy-4-chloro-phenyl) piperazin-1-yl ester, methods for its manufacture and its use for the preparation of medicaments
WO2013103634A3 (en) N-acylpeptide derivatives and their uses
MX2007006908A (en) Stabilisation of glucocorticoid esters with acids.
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
MX2009010483A (en) 5-oxo-isoxazoles as inhibitors of lipases and phospholipases.
WO2010118200A3 (en) Liposomal formulations of tocopheryl amides
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2011036676A3 (en) Stable cocrystals of temozolomide
CA2836069C (en) Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides
WO2011138037A3 (en) Solid tapentadol in non-crystalline form
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762418

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762418

Country of ref document: EP

Kind code of ref document: A2